Translating Sequoia Zanubrutinib Data into Real-World Clinical Practice
Chronic lymphocytic leukemia (CLL) is a disease that has seen significant changes in the treatment landscape with the advent of targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors. These novel agents have enabled the shift towards a chemotherapy-free approach to managing the disease, with the potential of durable disease control in a significant proportion […]
Translating Sequoia Zanubrutinib Data into Real-World Clinical Practice Read More »









